Unum Therapeutics Inc (NASDAQ:UMRX) has received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $5.88.
Several research firms have recently commented on UMRX. Wedbush reduced their price target on shares of Unum Therapeutics from $20.00 to $13.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Saturday, November 9th. Morgan Stanley reduced their price target on shares of Unum Therapeutics from $8.00 to $3.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. HC Wainwright reiterated a “buy” rating on shares of Unum Therapeutics in a research note on Tuesday, August 13th. Finally, Cowen reiterated a “hold” rating on shares of Unum Therapeutics in a research note on Monday, August 12th.
Shares of NASDAQ:UMRX traded down $0.06 during trading hours on Thursday, hitting $0.54. The company’s stock had a trading volume of 539,652 shares, compared to its average volume of 152,566. Unum Therapeutics has a 52 week low of $0.52 and a 52 week high of $5.90. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.96 and a quick ratio of 1.96. The company has a market capitalization of $18.46 million, a price-to-earnings ratio of -0.39 and a beta of 1.01. The firm’s fifty day moving average price is $0.98 and its 200 day moving average price is $1.88.
Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.07). Unum Therapeutics had a negative net margin of 388.07% and a negative return on equity of 96.07%. The business had revenue of $1.02 million during the quarter, compared to the consensus estimate of $4.41 million. On average, equities research analysts predict that Unum Therapeutics will post -1.42 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of UMRX. Tower Research Capital LLC TRC bought a new position in shares of Unum Therapeutics during the 3rd quarter worth approximately $31,000. Wedbush Securities Inc. bought a new position in shares of Unum Therapeutics during the 3rd quarter worth approximately $48,000. Susquehanna International Group LLP bought a new position in shares of Unum Therapeutics during the 2nd quarter worth approximately $62,000. Acadian Asset Management LLC raised its stake in shares of Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock worth $85,000 after acquiring an additional 18,717 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Unum Therapeutics during the 2nd quarter worth approximately $132,000. Hedge funds and other institutional investors own 43.02% of the company’s stock.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Featured Article: FAANG Stocks
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.